Associated Papers
The molecular biology of prostate cancer: current understanding and clinical implications.
Gandhi J et al.
Prostate Cancer and Prostatic Diseases, 2018
Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?
Nguyen-Dumont T et al.
Bmc Cancer, 2018
RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells.
Dayal S et al.
International Journal of Molecular Sciences, 2017
Prognostic role of genetic biomarkers in clinical progression of prostate cancer.
Alvarez-Cubero MJ et al.
Experimental & Molecular Medicine, 2015
RNase L restricts the mobility of engineered retrotransposons in cultured human cells.
Zhang A et al.
Nucleic Acids Research, 2014
The potential impact of adding genetic markers to clinical parameters in managing high-risk prostate cancer patients.
Alvarez-Cubero MJ et al.
Springerplus, 2013
Predictive value in the analysis of RNASEL genotypes in relation to prostate cancer.
Alvarez-Cubero MJ et al.
Prostate Cancer and Prostatic Diseases, 2012
Genetic variation in RNASEL associated with prostate cancer risk and progression.
Meyer MS et al.
Carcinogenesis, 2010
Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.
Beuten J et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2010
Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer.
Madsen BE et al.
Plos One, 2008
Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans.
Shook SJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2007
Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin.
Cybulski C
Hereditary Cancer in Clinical Practice, 2007
The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1.
Krüger S et al.
Cancer Letters, 2007
DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland.
Cybulski C et al.
Urologia Internationalis, 2007
RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis.
Li H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel.
Dagan E et al.
Familial Cancer, 2006
Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study.
Krüger S et al.
The Lancet. Oncology, 2005
Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
Rennert H et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2005
Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene.
Maier C et al.
British Journal of Cancer, 2005
Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.
Wiklund F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004
Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.
Nupponen NN et al.
Genes, Chromosomes & Cancer, 2004
Prostate cancer susceptibility genes: lessons learned and challenges posed.
Simard J et al.
Endocrine-related Cancer, 2003
RNASEL mutations in hereditary prostate cancer.
Chen H et al.
Journal of Medical Genetics, 2003
Implications for RNase L in prostate cancer biology.
Silverman RH
Biochemistry, 2003
Inherited predisposition to prostate cancer.
Verhage BA et al.
European Journal of Epidemiology, 2003
Perspective: prostate cancer susceptibility genes.
Simard J et al.
Endocrinology, 2002
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.
Rökman A et al.
American Journal of Human Genetics, 2002
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1.
Carpten J et al.
Nature Genetics, 2002